The National Institute for Health and Care Excellence (NICE) has recommended the use of Farydak (panobinostat) as a treatment for relapsed and/or refractory myeloma patients who have received at least two previous lines of treatment including Velcade® (bortezomib) and an immunomodulatory drug. This comes after an initial negative guidance issued in September which has now been successfully overturned following the submission of further evidence and feedback from stakeholders. Farydak is the first histone deacetylase inhibitor to be recommended by NICE for myeloma and final approval is expected shortly.


Read full article